Key result
Prompt heart failure therapy mitigates and may prevent cancer therapy cardiotoxicity in multidisciplinary cardio-oncology care.
Why the study?
Unique cardiovascular toxicities from modern cancer therapies are increasingly recognized, requiring collaborative cardio-oncology care to manage cardiotoxicity and long-term cardiovascular risk in cancer survivors.
Modern cancer therapy carries cardiovascular risks that require collaborative cardio-oncology management using advanced imaging, biomarkers, and prompt heart failure therapy.
Answers are grounded in this paper and cite their sources.
Multidisciplinary cardio-oncology care may improve management of therapy-related cardiotoxicity; leaves open optimal prevention and surveillance strategies pending prospective trials.
PURPOSE OF REVIEW: While targeted therapies have improved cancer outcomes, unique cardiovascular toxicities are increasingly recognized, particularly when administered sequentially after anthracyclines or radiation. Patients with cancer therapy-induced cardiotoxicity benefit from collaborative care involving cardiology and oncology, leading to a new interdisciplinary field called cardio-oncology. The present review will highlight contemporary clinical issues in cardio-oncology. RECENT FINDINGS: Recently, risk factors for cancer therapy-induced cardiotoxicity have been evaluated in real-world rather than in clinical trial patients. Biomarkers and advanced echocardiography are emerging as sensitive tools for preclinical identification of cancer therapy-induced cardiotoxicity. Single-center studies suggest that cancer therapy-induced cardiotoxicity responds to prompt heart failure medical treatment, and such therapy may even prevent cardiotoxicity. SUMMARY: Modern cancer therapy has short-term cardiac risk that may require collaborative management by clinicians with expertise in cardiology and oncology. The increased effectiveness of modern cancer therapy is resulting in a growing population of cancer survivors who are at long-term risk for cardiovascular disease. The present review of contemporary clinical issues in cardio-oncology will be of interest to healthcare providers who manage cardiotoxicity during cancer therapy, and who follow patients who survive cancer but face increased long-term cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Johnson et al. (2015) conducted a review in Cancer therapy-induced cardiotoxicity. Cancer therapy was evaluated. Cancer therapy-induced cardiotoxicity responds to prompt heart failure medical treatment, which may also prevent cardiotoxicity, highlighting the need for collaborative cardio-oncology care.
Synapse has enriched 10 related papers. Consider them for comparative context: